Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases, including in areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.
  • TickerBIIB
  • ISINUS09062X1037
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Laura Chico

KOL Call Takeaways: Don't Overlook Troriluzole (And Other Alzheimer's Thoughts)

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

Biogen Inc. - March 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Biogen Inc.: Update to credit analysis - Mature MS franchise and recent Alzheimer's setback will prompt M&A

Biogen's leadership positions in MS and spinal muscular atrophy and its strong credit metrics are tempered by a slowing growth outlook and pipeline execution risk.

Biogen Inc. - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's announces completion of a periodic review of ratings of Biogen Inc.

Announcement: Moody's announces completion of a periodic review of ratings of Biogen Inc.. Global Credit Research- 15 Feb 2019. New York, February 15, 2019-- Moody's Investors Service has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit.

Biogen Inc. - September 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Laura Chico

KOL Call Takeaways: Don't Overlook Troriluzole (And Other Alzheimer's Thoughts)

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

XLRP Opportunity Becoming Clear

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

ValuEngine Rating and Forecast Report for BIIB

MarketLine Department

Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report

Summary Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Sanofi Genzyme (Genzyme), a specialty care global business unit of Sanofi provides treatments with a focus on rare diseases, multiple sclerosis, immunology, and oncology. The major products of the company include Aldurazyme, Aubagio, Caprelsa tablets, Cerdelga capsules, Cerezyme, Clolar, Dupi...

MarketLine Department

Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Scope - Detailed information on Immunogen, Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Immunogen, Inc. in the form of a SWOT analysis - An in-depth view of the business model of Immunogen, Inc. including a breakdown and exami...

MarketLine Department

Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report

Summary Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. KeyHighlights Teva Pharmaceutical Industries Limited (Teva or 'the company') is a generic pharmaceutical company. The company develops, manufactures and markets generic, proprietary branded pharmaceuticals and active pharmaceutical ingredients. It offers specialty medicines for the t...

MarketLine Department

Sunesis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Sunesis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. KeyHighlights Sunesis Pharmaceuticals, Inc (Sunesis or 'the company') is a biopharmaceutical company that develops and commercializes oncology therapeutics for the treatment of hematologic and solid cancers. The company’s major products include Vosaroxin, TAK-580, SSN-510 and Vecabrutinib. Th...

MarketLine Department

Celgene Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Celgene Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Celgene Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weighte...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Small-Caps Testing Critical Resistance; Downgrading Communications As bullish developments pile up, the weight-of-the-evidence continues to support our belief that we may be in the early stages of a broad-based advance. There are some developments that leave us wanting more, but we are inching toward an outright bullish outlook. • The Failure of a Bearish Pattern is Bullish. We often know the implied direction (up or down) that a specific chart pattern is likely to resolve based on historical probabilities. But chart patterns are not infallible, and some technicians - present company include...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Health Care remains a bright spot and many individual names are breaking to RS highs. • Many Consumer Cyclical names such as NKE and CMG are emerging as leadership. • Many Semi and Semiconductor supplier names are staging Price and RS reversals.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Oversold rally continues Prepared comments from Fed Chair Powell last Friday have greatly diminished concerns of an overly aggressive Fed going forward. The combination of optimism surrounding U.S.-China trade talks and Powell's comments have led to a continuation of the oversold bounce which began on 12/26, and the S&P 500 is now trading just below the 12/19 pre-Fed rate hike area. ~2,350 on the S&P 500 remains the support level to monitor. A retest of this low remains the most likely scenario, though it is far from a guarantee due to the potential for a “V” reversal. While an array of facto...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch